• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail

Emend (aprepitant) capsules

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)  

 

August 2014

Summary View

ADVERSE REACTIONS

Postmarketing Experience
  • Nervous system disorders: Events of ifosfamide-induced neurotoxicity have been reported after aprepitant and ifosfamide coadministration.

 

March 2010

Summary View 

ADVERSE REACTIONS

Clinical Trials Experience
  • section (including Table 2) was updated to include the adverse experience data from the sponsor's completed postmarketing study.

CLINICAL STUDIES

Post-Marketing Trial
  • Entire Section Updated
  • In a postmarketing, multicenter, randomized, double-blind, parallel-group, clinical study in 848 cancer patients, the aprepitant regimen (N=430) was compared with a standard of care therapy (N=418) in patients receiving a moderately emetogenic chemotherapy regimen that included...